YOLFTbeta
Acumen Pharmaceuticals Inc

Acumen Pharmaceuticals Inc

ABOS · NASDAQ · Healthcare / Biotechnology

0.214USD-0.00 (-1.83%)

Price History

Full chart

Market Stats

Previous Close0.218
Open0.2229
Day Range0.1916 – 0.227
52-Week Range1.45 – 3.60
Volume2.78M
Market Cap161.63M
P/E (TTM)0.00
Forward P/E0.00
EPS-1.64
Dividend Yield0.00%
Beta0.38
50-Day Avg2.61
200-Day Avg2.50

About

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer's disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Daniel J. O'Connell M.B.A.
  • Employees60
  • Headquarters1210-1220 Washington St., Newton, MA, United States, 02465, USA
  • Websitehttps://acumenpharm.com

Leadership

  • Mr. Daniel J. O'Connell M.B.A.CEO & Director · b. 1970
  • Dr. James Doherty Ph.D.President & Chief Development Officer · b. 1968
  • Mr. Matt ZugaCFO & Chief Business Officer
  • Dr. Grant A. Krafft Ph.D.Co-Founder
  • Dr. Caleb E. Finch Ph.D.Co-Founder
  • Dr. William L. Klein Ph.D.Co-Founder
  • Mr. Russell Barton M.S.Chief Operating Officer · b. 1959
  • Ms. Kelly CarranzaSenior Vice President of Finance & Accounting and Corporate Controller
  • Ms. Alex Braun M.B.A.VP & Head of Investor Relations
  • Mr. Derek M. Meisner Esq., J.D.Chief Legal Officer & Corporate Secretary · b. 1971

Financials

Income Statement

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue1.70M1.44M1.44M0000
Growth (%)--15.38%0.00%-100.00%---
Cost of Revenue8.58M8.00M12.30M169.00K42.32M178.00K184.00K
Gross Profit-6.88M-6.56M-12.30M-169.00K-42.32M-178.00K-184.00K
Gross Margin-405.36%-456.89%-856.89%----
Operating Expense926.00K1.35M7.28M45.07M18.82M113.84M123.65M
Operating Income-7.80M-7.91M-19.58M-45.24M-61.14M-114.02M-123.83M
Operating Margin-459.93%-550.97%-1363.79%----
EBITDA119.00K-7.91M-100.60M-42.69M-51.61M-98.08M-116.93M
EBITDA Margin7.01%-550.97%-7005.71%----
Net Income-7.91M-7.33M-100.61M-42.86M-52.37M-102.33M-121.33M
Net Income Margin-465.94%-510.10%-7005.99%----
R&D8.58M8.00M12.30M32.36M42.32M93.80M104.89M
R&D as % of Total Revenue505.36%556.89%856.89%----
Interest Expense0081.02M2.38M581.00K4.07M4.22M
Interest Expense % of Total Revenue0.00%0.00%5642.20%----

Balance Sheet

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets7.32M44.43M230.33M196.59M310.13M238.99M122.83M
Total Liabilities18.74M63.02M5.15M7.81M43.15M57.18M52.40M
Total Equity-11.42M-18.59M225.18M188.78M266.97M181.82M70.43M
Cash6.55M43.78M122.16M130.10M66.89M35.63M53.99M
Total Debt--201.00K105.00K28.49M29.70M31.31M
Net Debt-6.55M-43.78M-122.16M-130.00M-38.40M-5.92M-22.68M

Cash Flow

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-6.82M-7.45M-17.96M-35.15M-43.06M-86.22M-115.54M
Investing Cash Flow-104.12M-104.12M-104.12M39.19M-171.67M48.03M133.93M
Financing Cash Flow6.24M44.67M200.47M3.91M151.75M6.93M-34.00K
Capital Expenditure40.00K40.00K40.00K161.00K21.00K16.00K88.00K
Free Cash Flow-6.82M-7.45M-18.00M-35.31M-43.09M-86.23M-115.63M
Dividends Paid----00-
FCF to OCF100.00%100.00%100.22%100.46%100.05%100.02%100.08%
Dividend Paid to FCF----0.00%0.00%-

Earnings

Report DateMar 31, 2020Mar 31, 2021Jun 2, 2021Aug 16, 2021Nov 15, 2021Mar 28, 2022May 16, 2022Aug 15, 2022Nov 14, 2022Mar 27, 2023May 9, 2023Aug 8, 2023Nov 13, 2023Mar 26, 2024May 14, 2024Aug 13, 2024Nov 12, 2024Mar 24, 2025May 13, 2025Aug 12, 2025Nov 12, 2025Mar 30, 2026May 12, 2026Aug 12, 2026Nov 11, 2026
EPS Estimate0.000.00-0.94-6.72-0.15-0.14-0.17-0.25-0.20-0.25-0.33-0.34-0.26-0.26-0.23-0.25-0.30-0.37-0.55-0.52-0.68-0.46-0.46-0.39-0.43
EPS Actual-4.88-64.40-0.94-7.91-0.10-0.42-0.23-0.25-0.26-0.32-0.28-0.28-0.24-0.28-0.25-0.34-0.50-0.62-0.48-0.68-0.44-0.41-0.33-0.45-
Surprise--0.00%-17.71%33.33%-200.00%-35.29%0.00%-30.00%-28.00%15.15%17.65%7.69%-7.69%-8.70%-36.00%-66.67%-69.49%12.73%-30.77%35.29%10.05%28.26%-15.38%-
Timing---After-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap161.63M
Enterprise Value88.14M
Trailing P/E0.00
Forward P/E0.00
Price / Sales538.78
Price / Book2.91
EPS-1.64
Book Value0.792
Revenue (TTM)329.00K
Gross Profit (TTM)-86.79M
EBITDA-105.37M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-120.51%
Return on Assets-45.77%
Shares Outstanding72.32M
Shares Float37.05M
Beta0.38
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 5 analystsTarget 7.60
  • Strong Buy
    5

Ownership Breakdown

Institutions
66.60%
Insiders
6.79%
Retail / Other
26.61%

Top Institutional Holders

  • RA Capital Management, LLC
    20.99M29.03%
  • Sands Capital Ventures, LLC
    3.72M5.14%
  • Alyeska Investment Group, L.P.
    2.45M3.39%
  • Franklin Templeton Inc
    2.31M3.19%
  • ADAR1 Capital Management LLC
    2.16M2.98%
  • Knollwood Investment Advisory LLC
    1.63M2.25%
  • Vanguard Capital Management, LLC
    1.51M2.08%
  • FMR Inc
    1.16M1.60%
  • Ikarian Capital, LLC
    1.05M1.46%
  • Hudson Bay Capital Management LP
    955.00K1.32%
  • Pathstone Holdings LLC
    859.11K1.19%
  • SG Americas Securities, LLC
    719.26K0.99%
  • Two Sigma Investments LLC
    622.88K0.86%
  • Susquehanna International Group, LLP
    601.48K0.83%
  • LAURION CAPITAL MANAGEMENT LP
    525.44K0.73%

Top Fund Holders

  • Franklin Biotechnology Discv A(acc)USD
    1.48M2.04%
  • Vanguard MStar Total Stk Mkt Idx Invest
    1.12M1.55%
  • iShares Russell 2000 ETF
    1.02M1.41%
  • Franklin Biotechnology Discovery A
    826.40K1.14%
  • Fidelity Small Cap Index
    514.41K0.71%